Risk of incident type 2 diabetes in patients with psoriatic arthritis: A systematic review and meta‐analysis of cohort studies

Yuan, Ziqi; Guo, Yan

doi:10.1111/1756-185x.14375

Cited by 5 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that patients with PsD are at increased risk of diabetes ( 4 ). In a systematic review and meta-analysis of cohort studies, the incidence of type 2 diabetes was 13.4 and 7.8/1000 patient-years in patients with PsA and non-rheumatic control subjects, respectively ( 29 ). In a systematic review of CV comorbidities in PsA, the prevalence of diabetes was found to be increased in patients with PsA compared with controls ( 30 ).…”

Section: Cardiometabolic Comorbidities In Psdmentioning

confidence: 99%

The cardiometabolic conditions of psoriatic disease

2022

View full text Add to dashboard Cite

Psoriasis (PsO) and psoriatic arthritis (PsA), together known as psoriatic disease (PsD), are immune-mediated diseases with a chronic and relapsing course that affect the skin, the joints or both. The pathophysiology of PsO is complex and involves abnormal expression of keratinocytes and infiltration of the skin with dendritic cells, macrophages, neutrophils and T lymphocytes. Around 30% of patients with PsO develop arthritis with axial and/or peripheral manifestations. Both PsO and PsA share similar Th1- and Th17-driven inflammation, with increased production of inflammatory cytokines, including TNFα, IFN-γ, IL-17, IL-22, IL-23 in the skin and the synovial membrane. PsD is associated with a high burden of cardiometabolic diseases such as hypertension, diabetes, dyslipidemia, obesity, metabolic syndrome and cardiovascular (CV) complications as compared to the general population. These comorbidities share common immunopathogenic pathways linked to systemic inflammation, and are associated with the extent and severity of the disease. Morever, they can influence treatment outcomes in PsD. In this short review, we summarize the available evidence on the epidemiology, clinical aspects and mechanisms of cardiometabolic conditions in patients with PsD. We also discuss the impact of targeted treatments such as methotrexate and biological agents on these cardiometabolic conditions.

show abstract

Section: Cardiometabolic Comorbidities In Psdmentioning

confidence: 99%

The cardiometabolic conditions of psoriatic disease

2022

View full text Add to dashboard Cite

show abstract

“…Conventional systemic treatments have been associated with an increased risk of major adverse cardiovascular events 11 ; however, targeted therapies have not shown an association 12 . Although defects in glucose metabolism among patients with psoriatic disease are not clearly established in previous studies, epidemiological studies suggest an association between type 2 diabetes and psoriatic disease 13 , 14 .…”

Section: Introductionmentioning

confidence: 86%

Risk of incident autoimmune diseases in patients with newly diagnosed psoriatic disease: a nationwide population-based study

Jung,

Kim,

Lee

et al. 2023

Sci Rep

View full text Add to dashboard Cite

There are limited large population-based cohort studies on the risk of incident autoimmune diseases among patients with newly diagnosed psoriatic disease. The objective of this study was to assess the risk of autoimmune diseases in patients with newly diagnosed psoriatic disease. Using the Korean National Health Insurance Service database, patients with newly diagnosed psoriatic disease between 2007 and 2019 were included. Comparators were randomly selected and matched according to age and sex. A total of 321,354 patients with psoriatic disease and 321,354 matched comparators were included in this study. Patients with psoriatic disease had a significantly higher risk of Crohn’s disease [adjusted hazard ratio (aHR), 1.95; 95% confidence interval (CI) 1.42–2.67], ulcerative colitis (aHR, 1.65; 95% CI 1.39–1.96), systemic lupus erythematosus (aHR, 1.86; 95% CI 1.34–2.57), rheumatoid arthritis (aHR, 1.63; 95% CI 1.52–1.76), ankylosing spondylitis (aHR, 2.32; 95% CI 1.95–2.77), alopecia areata (aHR, 1.41; 95% CI 1.35–1.46), and type 1 diabetes (aHR, 1.23; 95% CI 1.11–1.37). However, the risk of Graves’ disease, Hashimoto’s disease, Sjögren’s syndrome, and systemic sclerosis was not significantly different between the groups. In conclusion, patients with newly diagnosed psoriatic disease may have a significantly increased risk of incident autoimmune diseases.

show abstract

“…In a meta-analysis of 44 observational studies, the pooled OR was determined to be 1.76 (95% CI 1.59–1.96), with the highest risk for patients with PsA (OR 2.18, 95% CI 1.36–3.50) and in those with severe psoriasis [ 17 ]. In addition, another meta-analysis of five cohort studies found a 38% increase in the risk of diabetes among patients with PsA, with an incidence rate of 13.4 per 1000 patient-years [ 18 ]. Furthermore, an atherogenic lipid profile was reported among patients with psoriasis, compared to patients without psoriasis.…”

Section: Epidemiology Data Supporting the Association Between Psorias...mentioning

confidence: 99%

Managing the Patient with Psoriasis and Metabolic Comorbidities

Bellinato,

Maurelli,

Geat

et al. 2024

Am J Clin Dermatol

View full text Add to dashboard Cite

Epidemiological data demonstrate strong associations between psoriasis and metabolic comorbidities, including obesity, hypertension, diabetes mellitus, dyslipidemia, and non-alcoholic fatty liver disease. The presence of metabolic comorbidities significantly influences the selection and effectiveness of pharmacological treatments. Some drugs should be prescribed with caution in patients with metabolic comorbidities because of an increased risk of adverse events, while others could have a reduced effectiveness. The aim of this narrative review is to highlight the challenges that healthcare professionals may face regarding the management of psoriasis in patients with metabolic comorbidities. In the first part of the article, the epidemiological association between psoriasis and metabolic comorbidities and their pathogenetic mechanisms is summarized. The second part describes the efficacy and safety profile of conventional and biologic drugs in patients with selected metabolic comorbidities including obesity, non-alcoholic fatty liver disease/hepatic steatosis, and diabetes. Finally, the role of pharmacological and non-pharmacological interventions, such as diet, alcohol abstinence, physical activity, and smoking avoidance is discussed. In conclusion, the choice of the best approach to manage patients with psoriasis with metabolic comorbidities should encompass both tailored pharmacological and individualized non-pharmacological interventions.

show abstract

Risk of incident type 2 diabetes in patients with psoriatic arthritis: A systematic review and meta‐analysis of cohort studies

Cited by 5 publications

References 34 publications

The cardiometabolic conditions of psoriatic disease

The cardiometabolic conditions of psoriatic disease

Risk of incident autoimmune diseases in patients with newly diagnosed psoriatic disease: a nationwide population-based study

Managing the Patient with Psoriasis and Metabolic Comorbidities

Contact Info

Product

Resources

About